Therapeutic modulation of blood vessel growth holds promise for the prevention of limb ischemia in diabetic (DM) patients with peripheral artery disease (PAD). Epigenetic changes, namely, posttranslational histone modifications, participate in angiogenic response suggesting that chromatin-modifying drugs could be beneficial in this setting. Apabetalone (APA), a selective inhibitor of bromodomain (BRD) and bromodomain and extraterminal containing protein family (BET) proteins, prevents bromodomain-containing protein 4 (BRD4) interactions with chromatin thus modulating transcriptional programs in different organs. We sought to investigate whether APA affects angiogenic response in diabetes.
Results:
Compared with vehicle, APA restored tube formation and migration in human aortic endothelial cells (HAECs) exposed to high-glucose (HG) levels. Expression profiling of angiogenesis genes showed that APA prevents HG-induced upregulation of the antiangiogenic molecule thrombospondin-1 (THBS1). ChIP-seq and chromatin immunoprecipitation (ChIP) assays in HG-treated HAECs showed the enrichment of both BRD4 and active marks (H3K27ac) on THBS1 promoter, whereas BRD4 inhibition by APA prevented chromatin accessibility and THBS1 transcription. Mechanistically, we show that THBS1 inhibits angiogenesis by suppressing vascular endothelial growth factor A (VEGFA) signaling, while APA prevents these detrimental changes. In diabetic mice with hind limb ischemia, epigenetic editing by APA restored the THBS1/VEGFA axis, thus improving limb vascularization and perfusion, compared with vehicle-treated animals. Finally, epigenetic regulation of THBS1 by BRD4/H3K27ac was also reported in DM patients with PAD compared with nondiabetic controls.
Innovation:
This is the first study showing that BET protein inhibition by APA restores angiogenic response in experimental diabetes.
Conclusions:
Our findings set the stage for preclinical studies and exploratory clinical trials testing APA in diabetic PAD. Antioxid. Redox Signal. 36, 667–684.
Get full access to this article
View all access options for this article.
References
1.
AugusteG, RouhiL, MatkovichSJ, CoarfaC, RobertsonMJ, CzernuszewiczG, GurhaP, and MarianAJ. BET bromodomain inhibition attenuates cardiac phenotype in myocyte-specific lamin A/C-deficient mice. J Clin Invest, 130: 4740–4758, 2020.
2.
BaraniJ, NilssonJA, MattiassonI, LindbladB, and GottsaterA. Inflammatory mediators are associated with 1-year mortality in critical limb ischemia. J Vasc Surg, 42: 75–80, 2005.
3.
BastiaansenAJ, EwingMM, de BoerHC, van der Pouw KraanTC, de VriesMR, PetersEA, WeltenSM, ArensR, MooreSM, FaberJE, JukemaJW, HammingJF, NossentAY, and QuaxPH. Lysine acetyltransferase PCAF is a key regulator of arteriogenesis. Arterioscler Thromb Vasc Biol, 33: 1902–1910, 2013.
4.
BerdascoM and EstellerM. Clinical epigenetics: seizing opportunities for translation. Nat Rev Genet, 20: 109–127, 2019.
5.
BorckPC, GuoLW, and PlutzkyJ. BET epigenetic reader proteins in cardiovascular transcriptional programs. Circ Res, 126: 1190–1208, 2020.
6.
BrandtsJ and RayKK. Apabetalone—BET protein inhibition in cardiovascular disease and Type 2 diabetes. Future Cardiol, 16: 0017, 2020.
7.
CaporaliA, BackM, DaemenMJ, HoeferIE, JonesEA, LutgensE, MatterCM, Bochaton-PiallatML, SiekmannAF, SluimerJC, SteffensS, TunonJ, VindisC, WentzelJJ, Yla-HerttualaS, and EvansPC. Future directions for therapeutic strategies in post-ischaemic vascularization: a position paper from European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology. Cardiovasc Res, 114: 1411–1421, 2018.
CostantinoS, LibbyP, KishoreR, TardifJC, El-OstaA, and PaneniF. Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena. Eur Heart J, 39: 4150–4158, 2018.
10.
DabirP, MarinicTE, KrukovetsI, and SteninaOI. Aryl hydrocarbon receptor is activated by glucose and regulates the thrombospondin-1 gene promoter in endothelial cells. Circ Res, 102: 1558–1565, 2008.
11.
DelmoreJE, IssaGC, LemieuxME, RahlPB, ShiJ, JacobsHM, KastritisE, GilpatrickT, ParanalRM, QiJ, ChesiM, SchinzelAC, McKeownMR, HeffernanTP, VakocCR, BergsagelPL, GhobrialIM, RichardsonPG, YoungRA, HahnWC, AndersonKC, KungAL, BradnerJE, and MitsiadesCS. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell, 146: 904–917, 2011.
12.
DevaiahBN, Case-BordenC, GegonneA, HsuCH, ChenQ, MeerzamanD, DeyA, OzatoK, and SingerDS. BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin. Nat Struct Mol Biol, 23: 540–548, 2016.
13.
FadiniGP, AlbieroM, MillioniR, PoncinaN, RigatoM, ScottonR, BoscariF, BroccoE, ArrigoniG, VillanoG, TuratoC, BiasioloA, PontissoP, and AvogaroA. The molecular signature of impaired diabetic wound healing identifies serpinB3 as a healing biomarker. Diabetologia, 57: 1947–1956, 2014.
14.
FadiniGP, SpinettiG, SantopaoloM, and MadedduP. Impaired regeneration contributes to poor outcomes in diabetic peripheral artery disease. Arterioscler Thromb Vasc Biol, 40: 34–44, 2020.
15.
ForkC, GuL, HitzelJ, JosipovicI, HuJ, SzeKa WongM, PonomarevaY, AlbertM, SchmitzSU, UchidaS, FlemingI, HelinK, SteinhilberD, LeisegangMS, and BrandesRP. Epigenetic regulation of angiogenesis by JARID1B-induced repression of HOXA5. Arterioscler Thromb Vasc Biol, 35: 1645–1652, 2015.
16.
FraineauS, PaliiCG, AllanDS, and BrandM. Epigenetic regulation of endothelial-cell-mediated vascular repair. FEBS J, 282: 1605–1629, 2015.
17.
GaoT, Diaz-HirashiZ, and VerdeguerF. Metabolic signaling into chromatin modifications in the regulation of gene expression. Int J Mol Sci, 19: 4108, 2018.
18.
GebackT, SchulzMM, KoumoutsakosP, and DetmarM. TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays. Biotechniques, 46: 265–274, 2009.
19.
GilletteTG and HillJA. Readers, writers, and erasers: chromatin as the whiteboard of heart disease. Circ Res, 116: 1245–1253, 2015.
20.
GolledgeJ, BirosE, BingleyJ, IyerV, and KrishnaSM. Epigenetics and peripheral artery disease. Curr Atheroscler Rep, 18: 15, 2016.
21.
HamdaniN, CostantinoS, MuggeA, LebecheD, TschopeC, ThumT, and PaneniF. Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies. Eur Heart J, 42: 1940–1958, 2021.
22.
HeusleinJL, GorickCM, and PriceRJ. Epigenetic regulators of the revascularization response to chronic arterial occlusion. Cardiovasc Res, 115: 701–712, 2019.
23.
HiattWR, ArmstrongEJ, LarsonCJ, and BrassEP. Pathogenesis of the limb manifestations and exercise limitations in peripheral artery disease. Circ Res, 116: 1527–1539, 2015.
24.
IsenbergJS, Martin-MansoG, MaxhimerJB, and RobertsDD. Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat Rev Cancer, 9: 182–194, 2009.
25.
JahagirdarR, ZhangH, AzharS, TobinJ, AttwellS, YuR, WuJ, McLureKG, HansenHC, WagnerGS, YoungPR, SrivastavaRA, WongNC, and JohanssonJ. A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice. Atherosclerosis, 236: 91–100, 2014.
26.
Kalantar-ZadehK, SchwartzGG, NichollsSJ, BuhrKA, GinsbergHN, JohanssonJO, KulikowskiE, LebiodaK, TothPP, WongN, SweeneyM, Ray KK; BETonMACEInvestigators. Effect of Apabetalone on cardiovascular events in diabetes, CKD, and recent acute coronary syndrome: results from the BETonMACE randomized controlled trial. Clin J Am Soc Nephrol, 16: 705–716, 2021.
27.
KaluzaD, KrollJ, GesierichS, ManavskiY, BoeckelJN, DoebeleC, ZelentA, RossigL, ZeiherAM, AugustinHG, UrbichC, and DimmelerS. Histone deacetylase 9 promotes angiogenesis by targeting the antiangiogenic microRNA-17-92 cluster in endothelial cells. Arterioscler Thromb Vasc Biol, 33: 533–543, 2013.
28.
KeatingST and El-OstaA. Epigenetics and metabolism. Circ Res, 116: 715–736, 2015.
29.
KrishnaSM and GolledgeJ. The role of thrombospondin-1 in cardiovascular health and pathology. Int J Cardiol, 168: 692–706, 2013.
30.
LawlerJ. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med, 6: 1–12, 2002.
31.
LeBlancAJ and KelmNQ. Thrombospondin-1, free radicals, and the coronary microcirculation: the aging conundrum. Antioxid Redox Signal, 27: 785–801, 2017.
32.
MarsoSP and HiattWR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol, 47: 921–929, 2006.
33.
MasiS, AmbrosiniS, MohammedSA, SciarrettaS, LuscherTF, PaneniF, and CostantinoS. Epigenetic remodeling in obesity-related vascular disease. Antioxid Redox Signal, 34: 1165–1199, 2021.
MohammedSA, AmbrosiniS, LuscherT, PaneniF, and CostantinoS. Epigenetic control of mitochondrial function in the vasculature. Front Cardiovasc Med, 7: 28, 2020.
36.
NichollsSJ, RayKK, JohanssonJO, GordonA, SweeneyM, HallidayC, KulikowskiE, WongN, KimSW, and SchwartzGG. Selective BET protein inhibition with Apabetalone and cardiovascular events: a pooled analysis of trials in patients with coronary artery disease. Am J Cardiovasc Drugs, 18: 109–115, 2018.
37.
NorgrenL, HiattWR, DormandyJA, NehlerMR, HarrisKA, FowkesFG, and GroupTIW. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 45(Suppl, S): S5–S67, 2007.
38.
PaneniF, BeckmanJA, CreagerMA, and CosentinoF. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J, 34: 2436–2443, 2013.
39.
PaneniF, CostantinoS, BattistaR, CastelloL, CaprettiG, ChiandottoS, ScavoneG, VillanoA, PitoccoD, LanzaG, VolpeM, LuscherTF, and CosentinoF. Adverse epigenetic signatures by histone methyltransferase Set7 contribute to vascular dysfunction in patients with type 2 diabetes mellitus. Circ Cardiovasc Genet, 8: 150–158, 2015.
40.
PaneniF, CostantinoS, CastelloL, BattistaR, CaprettiG, ChiandottoS, D'AmarioD, ScavoneG, VillanoA, RustighiA, CreaF, PitoccoD, LanzaG, VolpeM, Del SalG, LuscherTF, and CosentinoF. Targeting prolyl-isomerase Pin1 prevents mitochondrial oxidative stress and vascular dysfunction: insights in patients with diabetes. Eur Heart J, 36: 817–828, 2015.
41.
PrattichizzoF, De NigrisV, MicheloniS, La SalaL, and CerielloA. Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: is low-grade inflammation the neglected component?. Diabetes Obes Metab, 20: 2515–2522, 2018.
42.
RayKK, NichollsSJ, BuhrKA, GinsbergHN, JohanssonJO, Kalantar-ZadehK, KulikowskiE, TothPP, WongN, SweeneyM, Schwartz GG; BETonMACE Investigators andCommittees. Effect of Apabetalone added to standard therapy on major adverse cardiovascular events in patients with recent acute coronary syndrome and type 2 diabetes: a randomized clinical trial. JAMA, 323: 1565–1573, 2020.
43.
ReineckeH, UnrathM, FreisingerE, BunzemeierH, MeyborgM, LudersF, GebauerK, RoederN, BergerK, and MalyarNM. Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherence. Eur Heart J, 36: 932–938, 2015.
44.
RenB, YeeKO, LawlerJ, and Khosravi-FarR. Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta, 1765: 178–188, 2006.
45.
Rodriguez-ManzanequeJC, LaneTF, OrtegaMA, HynesRO, LawlerJ, and Iruela-ArispeML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A, 98: 12485–12490, 2001.
46.
SawadaN and AranyZ. Metabolic regulation of angiogenesis in diabetes and aging. Physiology (Bethesda), 32: 290–307, 2017.
47.
TaniguchiY. The bromodomain and extra-terminal domain (BET) family: functional anatomy of BET paralogous proteins. Int J Mol Sci, 17: 1849, 2016.
48.
ThiruvoipatiT, KielhornCE, and ArmstrongEJ. Peripheral artery disease in patients with diabetes: epidemiology, mechanisms, and outcomes. World J Diabetes, 6: 961–969, 2015.
49.
TsujikawaLM, FuL, DasS, HallidayC, RakaiBD, StotzSC, SarsonsCD, GilhamD, DazeE, WasiakS, StuderD, RinkerKD, SweeneyM, JohanssonJO, WongNCW, and KulikowskiE. Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism. Clin Epigenetics, 11: 102, 2019.
50.
UccioliL, MeloniM, IzzoV, GiuratoL, MerollaS, and GandiniR. Critical limb ischemia: current challenges and future prospects. Vasc Health Risk Manag, 14: 63–74, 2018.
51.
WasiakS, DzoboKE, RakaiBD, KaiserY, VerslootM, BahjatM, StotzSC, FuL, SweeneyM, JohanssonJO, WongNCW, StroesESG, KroonJ, and KulikowskiE. BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes. Clin Epigenetics, 12: 166, 2020.
52.
WasiakS, GilhamD, DazeE, TsujikawaLM, HallidayC, StotzSC, RakaiBD, FuL, JahagirdarR, SweeneyM, JohanssonJO, WongNCW, and KulikowskiE. Epigenetic modulation by Apabetalone counters cytokine-driven acute phase response in vitro, in mice and in patients with cardiovascular disease. Cardiovasc Ther, 2020: 9397109, 2020.
53.
WasiakS, GilhamD, TsujikawaLM, HallidayC, CalosingC, JahagirdarR, JohanssonJ, SweeneyM, WongNC, and KulikowskiE. Downregulation of the complement cascade in vitro, in mice and in patients with cardiovascular disease by the BET protein inhibitor Apabetalone (RVX-208). J Cardiovasc Transl Res, 10: 337–347, 2017.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
